Ö. Kurt Şirin Et Al. , "PPAR? Pro12Ala and C161T polymorphisms, but not PPAR? L162V, are associated with osteoporosis risk in Turkish postmenopausal women.," ISTANBUL JOURNAL OF PHARMACY , vol.-, pp.1-10, 2019
Kurt Şirin, Ö. Et Al. 2019. PPAR? Pro12Ala and C161T polymorphisms, but not PPAR? L162V, are associated with osteoporosis risk in Turkish postmenopausal women.. ISTANBUL JOURNAL OF PHARMACY , vol.- , 1-10.
Kurt Şirin, Ö., Yılmaz Aydoğan, H., Uyar, M., & Can, A., (2019). PPAR? Pro12Ala and C161T polymorphisms, but not PPAR? L162V, are associated with osteoporosis risk in Turkish postmenopausal women.. ISTANBUL JOURNAL OF PHARMACY , vol.-, 1-10.
Kurt Şirin, Özlem Et Al. "PPAR? Pro12Ala and C161T polymorphisms, but not PPAR? L162V, are associated with osteoporosis risk in Turkish postmenopausal women.," ISTANBUL JOURNAL OF PHARMACY , vol.-, 1-10, 2019
Kurt Şirin, Özlem K. Et Al. "PPAR? Pro12Ala and C161T polymorphisms, but not PPAR? L162V, are associated with osteoporosis risk in Turkish postmenopausal women.." ISTANBUL JOURNAL OF PHARMACY , vol.-, pp.1-10, 2019
Kurt Şirin, Ö. Et Al. (2019) . "PPAR? Pro12Ala and C161T polymorphisms, but not PPAR? L162V, are associated with osteoporosis risk in Turkish postmenopausal women.." ISTANBUL JOURNAL OF PHARMACY , vol.-, pp.1-10.
@article{article, author={Özlem KURT ŞİRİN Et Al. }, title={PPAR? Pro12Ala and C161T polymorphisms, but not PPAR? L162V, are associated with osteoporosis risk in Turkish postmenopausal women.}, journal={ISTANBUL JOURNAL OF PHARMACY}, year=2019, pages={1-10} }